Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148176 | 0.83 | MCL1 (0.40) | KDM4EHTTPTPN1KMT2AMEN1 | |
| SCHEMBL7539654 | 0.81 | KDM4E (0.47) | KDM4EHTTPTPN1AKR1C3AKR1C2 | |
| SCHEMBL4143131 | 0.81 | ALDH1A1 (0.53) | KDM4EHTTAKR1C3AKR1C2KMT2A | |
| SCHEMBL4139411 | 0.81 | MAOB (0.45) | KDM4EKMT2AMAOB | |
| SCHEMBL4143169 | 0.78 | MCL1 (0.40) | KDM4EHTTPTPN1 | |
| SCHEMBL23116705 | 0.76 | KDM4E (0.37) | KDM4EHTTPTPN1KMT2ANQO1 | |
| SCHEMBL4143937 | 0.76 | AKR1C3 (0.52) | KDM4EHTTAKR1C3AKR1C2KMT2A | |
| SCHEMBL16963923 | 0.74 | CES2 (0.46) | AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL30193006 | 0.73 | AKR1C3 (0.45) | AKR1C3AKR1C2KMT2AAKR1C1PTGS1 | |
| SCHEMBL7828711 | 0.71 | KDM4E (0.51) | KDM4EKMT2AMEN1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7235569-B2 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | disclosed |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | TPH1, TPH2, HTR3A | KDM4E 2096/4885HTT 199/4885PTPN1 2981/4885 |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | KDM4E 2515/4885HTT 273/4885PTPN1 4607/4885 |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | TPH1, TPH2, HTR2C | KDM4E 2515/4885HTT 273/4885PTPN1 4607/4885 |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | TPH1, TPH2, HTR4 | KDM4E 2124/4885HTT 236/4885PTPN1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.